GlassScriptPhysician profile
Larry C Daniels
NPI 1700997160
$809.84
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $127 · 2021: $290 · 2022: $168.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $136.69 | 2021 | |
| Lilly USA, LLC | $131.86 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $124.98 | 2019 | |
| Novo Nordisk INC | $71.97 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $70.97 | 2022 | |
| Amgen INC. | $45.84 | 2021 | |
| Pfizer INC. | $39.08 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $36.41 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.34 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.50 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $27.86 | 2020-2022 | |
| Corcept Therapeutics | $18.15 | 2019 | |
| Amarin Pharma, INC. | $15.17 | 2019 | |
| Avanir Pharmaceuticals, INC. | $14.74 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.28 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Daniels listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.